trending Market Intelligence /marketintelligence/en/news-insights/trending/DP6AjrPGc5TRQUdnCobLhw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

GW Pharmaceuticals to sell US FDA priority review voucher to Biohaven for $105M

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


GW Pharmaceuticals to sell US FDA priority review voucher to Biohaven for $105M

GW Pharmaceuticals PLC will sell its U.S. Food and Drug Administration-granted rare pediatric disease priority review voucher to Biohaven Pharmaceutical Holding Co. Ltd. for $105 million.

Biohaven will use the priority review voucher for its new drug application for Zydis, or rimegepant, an oral treatment for migraines. The New Haven, Conn.-based company plans to submit the application in the second quarter of 2019, according to its March 18 press release.

The voucher, which can expedite a product candidate's review and time to approval, is transferable and can be sold without limitation.

GW Pharma will use the funds from the sale to advance its pipeline and further commercial development of Epidiolex, the first FDA-approved cannabis-derived therapy in the U.S., GW Pharma CEO Justin Gover said March 18. The U.K.-based pharmaceuticals company was awarded the priority review voucher when Epidiolex was approved in June 2018 for seizures associated with rare pediatric epileptic conditions.